Boeynaems J M, Van Coevorden A, Demolle D
Biochem Pharmacol. 1987 May 15;36(10):1629-35. doi: 10.1016/0006-2952(87)90047-5.
Suloctidil is a calcium antagonist with vascular relaxing activity and an antithrombotic agent: its antiplatelet action has been demonstrated in vivo, but is difficult to reproduce in vitro and the mechanism of this effect remains unknown. We have observed that suloctidil (10 microM) stimulated the release of prostacyclin (PGI2) from the rabbit aorta, the dog vena cava and the dog portal vein, in vitro. This effect could be explained by an increased mobilization of free arachidonic acid. Neither the inactive congener CP894S, nor the two calcium channel antagonists, verapamil and flunarizine, reproduced the stimulatory effect of suloctidil. Suloctidil acted selectively on the vascular endothelium: it stimulated the release of PGI2 from bovine aortic and human umbilical vein endothelial cells, but neither from the de-endothelialized rabbit aorta nor from the bovine aortic media. The stimulatory effect of suloctidil on the release of the platelet inhibitor PGI2 from the vascular endothelium might contribute to the known antiplatelet and antithrombotic activity of this drug.
其抗血小板作用已在体内得到证实,但在体外难以重现,且这种作用的机制尚不清楚。我们观察到,舒洛地尔(10微摩尔)在体外可刺激兔主动脉、犬腔静脉和犬门静脉释放前列环素(PGI2)。这种作用可以通过游离花生四烯酸的动员增加来解释。无活性的同系物CP894S以及两种钙通道拮抗剂维拉帕米和氟桂利嗪均未重现舒洛地尔的刺激作用。舒洛地尔选择性地作用于血管内皮:它刺激牛主动脉和人脐静脉内皮细胞释放PGI2,但不刺激去内皮的兔主动脉或牛主动脉中膜释放PGI2。舒洛地尔对血管内皮释放血小板抑制剂PGI2的刺激作用可能有助于该药物已知的抗血小板和抗血栓形成活性。